If you are wondering whether Novartis is priced attractively right now or if the recent run has already baked in the upside, this article walks through what the current share price might be implying.
After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...
Novartis presents key market opportunities through its focus on digital transformation, innovation programs, and strategic tech initiatives. It leverages partnerships, product launches, investments, ...
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations. Still, the company's pipeline looks likely to support ongoing growth.
The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies.
FRANKFURT, Feb 4 (Reuters) - Novartis forecast its first annual drop in operating profit in a decade on Wednesday, even as it indicated that long term, the company could potentially offset the ...
Novartis AG (NYSE:NVS) is among the most profitable healthcare stocks to buy. On January 27, Graham Parry from Citi began coverage of Novartis AG (NYSE:NVS) with a Buy rating and a price target of CHF ...
In its upcoming report, Novartis (NVS) is predicted by Wall Street analysts to post quarterly earnings of $1.99 per share, reflecting an increase of 0.5% compared to the same period last year.
Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro Pharmaceuticals. The Swiss Big Pharma is handing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results